GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Total Liabilities : ₹0 Mil (As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is GlaxoSmithKline Pharmaceuticals Total Liabilities?

GlaxoSmithKline Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2024 was ₹0 Mil.

GlaxoSmithKline Pharmaceuticals's quarterly Total Liabilities increased from Jun. 2024 (₹0.00 Mil) to Sep. 2024 (₹20,733.00 Mil) but then declined from Sep. 2024 (₹20,733.00 Mil) to Dec. 2024 (₹0.00 Mil).

GlaxoSmithKline Pharmaceuticals's annual Total Liabilities declined from Mar. 2022 (₹19,703.22 Mil) to Mar. 2023 (₹15,853.12 Mil) but then increased from Mar. 2023 (₹15,853.12 Mil) to Mar. 2024 (₹17,789.78 Mil).

GlaxoSmithKline Pharmaceuticals Total Liabilities Historical Data

The historical data trend for GlaxoSmithKline Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pharmaceuticals Total Liabilities Chart

GlaxoSmithKline Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

13,149.36

16,363.88

19,703.22

15,853.12

17,789.78

GlaxoSmithKline Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															-	17,789.78	-	20,733.00	-

GlaxoSmithKline Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

GlaxoSmithKline Pharmaceuticals's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	15249.461	+	(64.691	+	2475.626
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	17,790

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	35566.175	-	17776.397
	=	17,790

GlaxoSmithKline Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	N/A

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	N/A	-	N/A
	=	N/A

GlaxoSmithKline Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

GlaxoSmithKline Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pharmaceuticals Ltd (NSE:GLAXO) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

500660:India

Address

Dr. Annie Besant Road, GSK House, Worli, Mumbai, MH, IND, 400030

Website

https://www.gsk-india.com

GlaxoSmithKline Pharmaceuticals Ltd is an India-based subsidiary of GlaxoSmithKline plc. GSK India develops and manufactures medicines, vaccines, and consumer products. Its medicines portfolio includes prescription drugs for conditions that include asthma, infectious diseases, mental health, and digestion, as well as nonprescription nutrition and cosmetic products. Its vaccines product line includes treatments for conditions such as influenza, HPV, hepatitis, and measles. Its consumer healthcare products include Horlicks-brand packaged food and beverage powders among other retail products. The company derives majority of its revenue from India.

GlaxoSmithKline Pharmaceuticals Headlines

No Headlines